FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4384919838> ?p ?o ?g. }

• W4384919838 abstract "Background Hematopoietic stem cell transplantation (HSCT) is an important treatment for T-cell lymphoblastic lymphoma/leukemia (T-LBL). To compare the efficacy and influencing factors of autologous hematopoietic stem cell transplantation (auto-HSCT) with those of allogeneic hematopoietic stem cell transplantation (allo-HSCT) from different donors for the treatment of T-cell lymphoblastic lymphoma/leukemia (T-LBL) and provide a basis for selection of appropriate transplant methods and donors. Methods To provide evidence of appropriate transplant methods for these patients, we retrospectively summarized the clinical characteristics of 75 T-LBL patients receiving HSCT at Henan Cancer Hospital between March 2012 and October 2021. Overall survival (OS), progression-free survival (PFS), cumulative incidence of relapse (CIR), non-relapse mortality (NRM), and related factors affecting efficacy were analyzed. Results The 3-year CIR (39.9% vs 31.1%, P=0.745), 3-year PFS (60.1% vs 49.6%, P=0.434), and 3-year OS (62.8% vs 53.0%, P=0.450) were not significantly different between the auto-HSCT and allo-HSCT groups. However, the 3-year NRM was significantly higher in the allo-HSCT group (0% vs 27.2%, P=0.033). Multivariate analysis showed that the first complete remission (CR1) after HSCT was an independent influencing factor of higher OS (HR=2.498, P=0.029) and PFS (HR=2.576, P=0.016). The absence of mediastinal invasion in patients receiving HSCT was an independent influencing factor of better PFS (HR=2.977, P=0.029) and lower CIR (HR=4.040, P=0.027). With respect to the impact of donor source, the NRM in the unrelated donor (URD) and haploid donor (HPD) groups was significantly higher than that in the auto-HSCT group (P=0.021 and P=0.003, respectively), while there was no significant difference between matched sibling donors (MSD) and auto-HSCT. Compared with the MSD-HSCT group, the auto-HSCT group showed an increasing trend in 3-year CIR (39.9 ± 11.1% vs 32.6 ± 11.2%, P=0.697) and a lower trend in 3-year OS (62.8 ± 11.4% vs 64.4 ± 12.2%, P=0.929). Conclusions HSCT is an effective consolidation treatment option for patients with T-LBL without mediastinal invasion and with CR1 before transplantation. For CR1 patients, auto-HSCT and MSD-HSCT are effective modalities for improving survival. In non-CR1 patients without an MSD, matched unrelated donors and haploidentical donor transplantations are the best treatment options to reduce relapse and improve prognosis." @default.
• W4384919838 created "2023-07-21" @default.
• W4384919838 creator A5003253320 @default.
• W4384919838 creator A5005385651 @default.
• W4384919838 creator A5014270790 @default.
• W4384919838 creator A5018083369 @default.
• W4384919838 creator A5033193441 @default.
• W4384919838 creator A5045767607 @default.
• W4384919838 creator A5049236401 @default.
• W4384919838 creator A5050450526 @default.
• W4384919838 creator A5072453373 @default.
• W4384919838 creator A5090241332 @default.
• W4384919838 creator A5090455604 @default.
• W4384919838 creator A5091366322 @default.
• W4384919838 creator A5092506279 @default.
• W4384919838 date "2023-07-20" @default.
• W4384919838 modified "2023-10-18" @default.
• W4384919838 title "Selection of hematopoietic stem cell transplantation for T-cell lymphoblastic lymphoma" @default.
• W4384919838 cites W133289461 @default.
• W4384919838 cites W1521760863 @default.
• W4384919838 cites W1641346937 @default.
• W4384919838 cites W1801876107 @default.
• W4384919838 cites W1847661419 @default.
• W4384919838 cites W1969481809 @default.
• W4384919838 cites W1974251353 @default.
• W4384919838 cites W1999105034 @default.
• W4384919838 cites W2000402065 @default.
• W4384919838 cites W2006083195 @default.
• W4384919838 cites W2037327334 @default.
• W4384919838 cites W2050152294 @default.
• W4384919838 cites W2058809104 @default.
• W4384919838 cites W2079290872 @default.
• W4384919838 cites W2089034243 @default.
• W4384919838 cites W2092120000 @default.
• W4384919838 cites W2097501739 @default.
• W4384919838 cites W2104165703 @default.
• W4384919838 cites W2122780124 @default.
• W4384919838 cites W2128237169 @default.
• W4384919838 cites W2141819662 @default.
• W4384919838 cites W2145593916 @default.
• W4384919838 cites W2149306989 @default.
• W4384919838 cites W2173629810 @default.
• W4384919838 cites W2196003008 @default.
• W4384919838 cites W2300689292 @default.
• W4384919838 cites W2331693462 @default.
• W4384919838 cites W2484127286 @default.
• W4384919838 cites W2546298360 @default.
• W4384919838 cites W2556452623 @default.
• W4384919838 cites W2588107243 @default.
• W4384919838 cites W2620798361 @default.
• W4384919838 cites W2809164184 @default.
• W4384919838 cites W2912098096 @default.
• W4384919838 cites W2981497631 @default.
• W4384919838 cites W2990370730 @default.
• W4384919838 cites W2990689630 @default.
• W4384919838 cites W2997043852 @default.
• W4384919838 cites W3111466059 @default.
• W4384919838 cites W3160418865 @default.
• W4384919838 cites W3211304670 @default.
• W4384919838 cites W4211099466 @default.
• W4384919838 cites W4245855481 @default.
• W4384919838 cites W2118661946 @default.
• W4384919838 doi "https://doi.org/10.3389/fonc.2023.1193237" @default.
• W4384919838 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37546390" @default.
• W4384919838 hasPublicationYear "2023" @default.
• W4384919838 type Work @default.
• W4384919838 citedByCount "0" @default.
• W4384919838 crossrefType "journal-article" @default.
• W4384919838 hasAuthorship W4384919838A5003253320 @default.
• W4384919838 hasAuthorship W4384919838A5005385651 @default.
• W4384919838 hasAuthorship W4384919838A5014270790 @default.
• W4384919838 hasAuthorship W4384919838A5018083369 @default.
• W4384919838 hasAuthorship W4384919838A5033193441 @default.
• W4384919838 hasAuthorship W4384919838A5045767607 @default.
• W4384919838 hasAuthorship W4384919838A5049236401 @default.
• W4384919838 hasAuthorship W4384919838A5050450526 @default.
• W4384919838 hasAuthorship W4384919838A5072453373 @default.
• W4384919838 hasAuthorship W4384919838A5090241332 @default.
• W4384919838 hasAuthorship W4384919838A5090455604 @default.
• W4384919838 hasAuthorship W4384919838A5091366322 @default.
• W4384919838 hasAuthorship W4384919838A5092506279 @default.
• W4384919838 hasBestOaLocation W43849198381 @default.
• W4384919838 hasConcept C120665830 @default.
• W4384919838 hasConcept C121332964 @default.
• W4384919838 hasConcept C126322002 @default.
• W4384919838 hasConcept C143998085 @default.
• W4384919838 hasConcept C203014093 @default.
• W4384919838 hasConcept C2776090121 @default.
• W4384919838 hasConcept C2777408962 @default.
• W4384919838 hasConcept C2777478502 @default.
• W4384919838 hasConcept C2779338263 @default.
• W4384919838 hasConcept C28328180 @default.
• W4384919838 hasConcept C2911091166 @default.
• W4384919838 hasConcept C54355233 @default.
• W4384919838 hasConcept C61511704 @default.
• W4384919838 hasConcept C71924100 @default.
• W4384919838 hasConcept C86803240 @default.
• W4384919838 hasConcept C88879693 @default.
• W4384919838 hasConcept C8891405 @default.
• W4384919838 hasConceptScore W4384919838C120665830 @default.

• next